Corporate Governance15 Jun 2026, 09:30 pm
Corona Remedies Files FY26 Business Responsibility and Sustainability Report
AI Summary
Corona Remedies Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as mandated by SEBI regulations. The report, which forms part of the company's Annual Report, details its corporate identity, operational locations, employee statistics, and market reach. The company reported 100% of its turnover from the manufacturing of pharmaceutical products and serves a diverse customer base including pharmacies, hospitals, and other consumers. Exports contributed approximately 4.06% to the total turnover.
Key Highlights
- Corona Remedies filed its FY26 BRSR report as per SEBI mandate.
- Report covers corporate details, operations, and market reach.
- 100% turnover from pharmaceutical product manufacturing.
- Exports accounted for 4.06% of total turnover.
- Company serves diverse B2C customers including pharmacies and hospitals.
Price Impact
More from CORONA